GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Amicogen 092040.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

963

+0.42%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Amicogen

Its shares trade on KOSDAQ under the ticker 092040.KQ. It has been listed since 12 September 2013. In the fiscal year to 31 December 2025, it reported revenue of ₩41.98bn and a net loss of ₩29.96bn. At that date it held total assets of ₩231.86bn and shareholders' equity of ₩94.57bn.

Amicogen, Inc. engages in the development and sale of enzyme products and functional food materials. The company is headquartered in Jinju, Gyeongsangnam-Do. The company went IPO on 2013-09-12. The Company’s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The firm distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Sept 2013

Leadership

Pay as last reported

  • Cheol ParkChief Executive Officer, Vice President, Director
  • Yeong Su KimManaging Director
  • Hak Su KimInternal Auditor
  • Jun Ho KimDirector
  • Yong Cheol ShinDirector, since 2023
  • Ji Seong SohDirector
  • Chang Yeong HanNon-Executive Independent Director
  • Sang Cheol KimNon-Executive Independent Director
  • Sun Yong KimNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Jinju, Gyeongsangnam-Do, South Korea
  • Offers a diverse product portfolio including enzymes, NAG, pinitol, DCI, collagen peptides, and protein A chromatography resins
  • Operates in both domestic and international markets including China, Japan, the United States, Germany, and Thailand

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on competitive advantages or unique selling points

Opportunities

  • Expansion into new international markets beyond current presence in China, Japan, the United States, Germany, and Thailand
  • Growth potential in the biotechnology sector within the health care industry
  • Increasing demand for enzyme products and functional food materials globally

Threats

  • Competition from other biotechnology firms in the health care sector
  • Regulatory challenges in international markets
  • Dependence on specific product lines without diversification details provided

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.